Innovation | Novartis United States of America

Media Release
Nov 11, 2018
New Novartis study supports Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilized heart failure patients
Media Release
Nov 02, 2018
Novartis data at ASH and SABCS show strength of pipeline and portfolio in hematology and oncology
Media Release
Oct 29, 2018
Novartis wins esteemed Prix Galien Foundation Best Biotechnology Product Award for CAR-T cell therapy, Kymriah®
Media Release
Dec 01, 2018
Novartis announces new crizanlizumab (SEG101) data analysis in sickle cell disease, and investment in SENTRY clinical program
Media Release
Nov 16, 2018
FDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designation for additional new indication
Media Release
Nov 14, 2018
Novartis to fund five innovative ideas to support patients and the sickle cell community
Media Release
Dec 06, 2018
Novartis investigational BYL719 (alpelisib) plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 analyses
Media Release
Dec 02, 2018
Real-world data show Novartis drug Promacta® improves outcomes for ITP patients compared to other second-line therapies
Media Release
Dec 01, 2018
Novartis announces longer-term analyses from pivotal Kymriah® trials that showed durable responses are maintained in patients with advanced blood cancers
Media Release
Jan 28, 2019
Novartis data show psoriasis patients treated with Cosentyx® reported improvements in quality of life measures as early as Week 4
Media Release
Jan 08, 2019
Novartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease
Media Release
Dec 08, 2018
Novartis data demonstrates consistent efficacy and tolerability of Kisqali® combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease